US 12,391,927 B2
Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders
Maria Siemionow, Chicago, IL (US)
Assigned to The Board of Trustees of the University of Illinois, Urbana, IL (US)
Appl. No. 16/761,561
Filed by THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
PCT Filed Nov. 28, 2018, PCT No. PCT/US2018/062736
§ 371(c)(1), (2) Date May 5, 2020,
PCT Pub. No. WO2019/108584, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/591,397, filed on Nov. 28, 2017.
Prior Publication US 2020/0263141 A1, Aug. 20, 2020
Int. Cl. C12N 5/16 (2006.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 35/34 (2015.01); A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/41 (2025.01); C12N 5/073 (2010.01); C12N 5/078 (2010.01)
CPC C12N 5/16 (2013.01) [A61K 35/28 (2013.01); A61K 35/34 (2013.01); A61K 40/10 (2025.01); A61K 40/22 (2025.01); A61K 40/416 (2025.01); A61K 40/418 (2025.01); C12N 5/0605 (2013.01); C12N 5/0634 (2013.01); A61K 2035/122 (2013.01); A61K 2035/124 (2013.01); A61K 2239/31 (2023.05)] 6 Claims
 
1. A multi-chimeric cell comprising an ex vivo fusion of three or more cells selected from the group consisting of hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, satellite cells, and combinations thereof, from three or more different donors, wherein the multi-chimeric cell is in a pharmaceutically acceptable carrier or aqueous medium; and each of the three or more cells are labeled with a different label and the multi-chimeric cell resulting from the fusion can be isolated by cell sorting based on the presence of each of the different labels; and at least one of the three or more cells is a mesenchymal stem cell, myoblast, pericyte, or satellite cell.